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Purpose: The purpose of this study was to determine the effectiveness of percutaneous 
transluminal angioplasty (PTA) for treatment of patients with localized stenosis of the 
infrageniculate popfiteal artery and tibio-peroneal trunk (IGPA). 
Methods: The records of 25 patients undergoing IGPA PTA from 1983 to 1993 were 
reviewed. Patients underwent follow-up with clinical examinations, ankle-brachial 
indexes, Duplex scanning, and arteriography. Demographic variables and cardiovascular 
risk factors were analyzed and correlated with outcome. 
Results: Mean follow-up was 44 months. With life-table analysis, clinical and hemody- 
namic success was 59%, 32%, and 20% at 1, 2, and 3 years, respectively. Average time to 
recurrence was 17 months. Sixteen patients required asubsequent procedure; two had only 
repeat PTA, six had repeat PTA followed by arterial bypass, and eight had bypass alone. 
The mean additional benefit of repeat PTA was 8 months. Eleven of the 14 patients reated 
with bypass became symptom-free with patent grafts at a mean follow-up of 52 months. 
No risk factor was statistically significant in predicting success of IGPA PTA. 
Conclusions: IGPA PTA is an expensive t mporizing measure with a high rate of recurrence 
requiring subsequent intervention. The procedure should be restricted to patients with 
limited life expectancy orcontraindications to operation. (J VAsc SURG 1995 ;22:457-65.) 
Dotter and Judldns 1 first reported infrageniculate 
arterial dilation with concentric tapered catheters in 
1964, but it was not until Gruntzig and Hopf f  2 
introduced the coaxial balloon catheter in 1974 that 
percutaneous transluminal ngioplasty (PTA) of the 
infrageniculate popliteal artery and tibio-peroneal 
trunk (IGPA) became more widely used. Continued 
refinement in catheter and balloon design, improve- 
ments in arterial imaging, and increasing experience 
with PTA have improved the success of IGPA 
dilatation. Some reports now recommend IGPA 
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PTA in preference to arterial reconstruction for 
treatment of patients with localized distal popliteal 
artery or tibioperoneal trunk stenosis? ,4
In spite of the attractiveness of PTA for treatment 
of patients who would otherwise require infragenic- 
ulate arterial bypass, we were concerned that PTA did 
not offer comparable benefit o operation. In addi- 
tion, it was our observation that PTA often failed and 
that many patients required subsequent revascular- 
ization. Therefore this review was undertaken to (1) 
determine the short- and long-term clinical and 
hemodynamic benefit, (2) identify demographic 
variables and arteriographic findings associated with 
long-term success, and (3) compare the cost and 
benefit o better define indications for the procedure. 
MATERIAL  AND METHODS 
Between 1983 and 1993, more than 400 patients 
underwent PTA at Cedars-Sinai Medical Center in 
Los Angeles for treatment of  femoropopliteal occlu- 
sive disease. Of  these patients, 25 were treated for a 
localized IGPA stenosis ranging from 1 to 5 cm in 
length, and this group forms the basis of this report. 
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All patients had diagnostic arteriography per- 
formed by an interventional radiologist, and the 
decision to proceed with PTA was made after joint 
consultation between the radiologist and vascular 
surgeon. Most patients underwent initial arteriogra- 
phy with PTA performed the following day. Twenty- 
two dilations were performed by the radiologist in 
the arteriography suite, and three were performed by 
the attending vascular surgeon in the operating 
room. 
All 25 patients were evaluated with ankle-brachial 
indexes and arterial waveforms before PTA. Com- 
plete color flow duplex scans (Acuson 128, Acuson 
Corporation, Mountain View, Calif.) of the affected 
lower extremity were obtained on 11 patients. Based 
on duplex scan, segmental Doppler pressures, and 
femoral artery waveforms, no patient had hemody- 
namically significant aortoiliac occlusive disease. On 
arteriography, no patient had iliac artery or superfi- 
cial femoral artery stenosis resulting in more than 
50% diameter reduction. All patients had stenosis of 
the infrageniculate popliteal artery or tibio-peroneal 
trunk exceeding 75% diameter reduction compared 
with the distal artery. 
Twenty-four (96%) of the 25 patients had 
continuous in-line flow through at least one tibial 
artery into the foot. One patient had occlusion of the 
three tibial arteries in the distal calf with reconstitu- 
tion of the pedal arch via collateral vessels. In most 
cases the popliteal stenosis was severe, and patients 
may have had occlusion of pedal arteries or microvas- 
cular disease. This possibility may account for the 
development ofrest pain or an ischemic ulcer in these 
patients. 
Before the dilation was performed, 13 (62%) of 
the 25 patients received aspirin and nine (36%) 
received persantine. All patients continued to receive 
aspirin after PTA was performed. No patient under- 
went a simultaneous arterial reconstruction or 
thrombolytic therapy. Patients were given 3000 U 
heparin systemically after arterial cannulation was 
performed, and the heparin was not reversed with 
protamine after the procedure was completed. Two 
patients were treated with a continuous heparin 
infusion for 48 hours after PTA was performed, but 
no patient received subsequent heparin or warfarin 
anticoagulation. 
All procedures were performed with coaxial 
Seldinger technique through an arterial sheath via an 
ipsilateral or contralateral femoral approach. A steer- 
able guidewire or a coated 0.018-inch glidewire and 
catheter was used to cross the lesion. A low-profile 
polyethylene balloon catheter (Meditech ultrathin or 
Meditech sub4, Meditech, Watertown, Mass.) with 
external balloon diameter of 3 to 5 mm was used for 
dilatation. Patients were premedicated with sublin- 
gual nifedipine (10 mg) and intraarterial nitroglyc- 
erin (100 to 200 txg bolus) at the discretion of the 
treating physician to minimize vasospasm. Patients 
were observed in the hospital for at least 24 hours 
after the procedure. 
Technical success was defined as a residual IGPA 
stenosis of less than 30% on arteriography compared 
with the distal artery. Clinical success was defined as 
an improvement in symptoms or satisfactory wound 
healing. Hemodynamic success was defined as an 
increase in the ankle-brachial index (ABI) of more 
than 0.10 or an improvement in tibial artery wave- 
forms for patients with calcified or noncompressible 
arteries. 
During follow-up patients had serial ABI with 
clinical examinations at3-month intervals for the first 
year and at least semiannually thereafter. All patients 
with recurrent symptoms, unsatisfacto~ wound 
healing, or hemodynamic deterioration underwent 
urgent duplex scanning or arteriography. Patients 
who remained without symptoms had routine duplex 
scanning at the discretion of the attending vascular 
surgeon. During follow-up 15 of the 25 patients 
underwent arteriography, and 10 underwent color- 
flow duplex scanning. 
Age, sex, cardiovascular risk factors, and previous 
vascular procedures were recorded for each patient. 
The number of patent tibial arteries was used to 
classify nmoff as poor (0 or one patent ibial vessel) 
or good (two or three patent arteries). The indication 
for PTA was classified as ischemic ulceration, rest 
pain, or claudication, and the initial ABI was 
examined separately for each indication. 
Demographic variables, cardiovascular risk fac- 
tors, indication for the procedure, and patency of 
tibial artery runoff were statistically analyzed and 
correlated with outcome. An abnormal outcome was 
defined as hemodynamic deterioration asdetermined 
by ABI or arterial waveforms combined with recur- 
rent stenosis on arteriography. Discrete and continu- 
ous variables were examined, and relative risk of an 
abnormal outcome was determined by the Cox 
regression model. The likelihood ratio statistic was 
used with statistical significance defined asp < 0.05. 
The Kaplan-Meier product limit method was used to 
create life-table plots with failure time equal to the 
time from procedure to recurrence. 
Results were analyzed and reported in accordance 
with the reporting standards for lower extremity 
arterial endovascular procedures. <6 Treatment out- 
JOURNAL OF VASCULAR SURGERY 
Volume 22, Number 4 Treiman et aL 459 
come was based on intent to treat. To allow for 
statistical analysis, patients who did not undergo 
successful dilation were recorded as failure at 
time = 0. 
RESULTS 
The 25 patients (17 men, 8 women) ranged in age 
from 53 to 87 (mean 71 years). Paticnt demographic 
information and cardiovascular risk factors are listed 
in Table I. Three patients had undergone a previous 
arterial procedure: two had resection of an abdominal 
aortic aneurysm, and one had an aortobifemoral 
bypass. 
Thc indication for PTA was rest pain in 14 (56%) 
patients (mean ABI 0.54), ischemic ulccration in six 
(24%) patients (mean ABI 0.50), and clandication i
fivc (20%) patients (mean ABI 0.65). The overall 
mcan preprocedure ABI was 0.55. Fourteen (56%) 
patients had two- or three-vessel runoff, 10 (40%) 
had onc-vessel runoff, and onc had no patent ibial 
artery. 
PTA was technically successful in 22 of the 25 
patients as determined by complction arteriography, 
including 12 of the 14 patients with rest pain, five of 
the six with ischemic ulceration, and the five with 
claudication. All 22 patients had early hemodynamic 
success with an increase in the mean ABI of 0.34 
(0.55 to 0.89) and with an improvemcnt in tibia] 
artery waveforms. In each case technical success was 
associated with early clinical improvement. 
Successful dilation could not be performed in 
three (12%) patients, with two of the technical 
failures occurring before smaller guidewires and 
glidewires were routinely available. In all three cases 
the wire could not be accurately positioned across the 
lesion, and no PTA was performed. These three 
patients underwent an elective femorotibial artery 
bypass during the same hospitalization, and the 
attempted PTA did not adversely affect the subse- 
quent operative procedure. 
There was no death or major morbidity associated 
with IGPA PTA. Two patients had a groin he- 
matoma necessitating blood transfusion but not 
requiring operative repair. One patient had a 
popliteal artery dissection that resolved uring ob- 
servation. 
The overall average charge to the patient of 
the PTA, including both hospital and professional 
charges, ranged from $18,000 to $25,000. The 
average charge was $21,000. Most patients under- 
went initial diagnostic arteriography followed by a 
discussion of treatment options and then subsequent 
PTA in either the radiology suite or operating room. 
Table I. Patient characteristics and 
cardiovascular risk factors 
Variable No. 
Patients 25 
Male 17 
Female 8 
Mean age (yrs) 71 
Heart disease 18 
Hypertension 15 
Diabetes mellims 12 
Cigarette use 9 
Kidney disease 3 
Hyperlipidemia 1 
Heart disease determined by history of MI, angina, arrhythmia or 
congestive heart failure. 
Hypertension defined as requiring medication to control blood 
pressure. 
Diabetes determined by history. 
Kidney disease defined as serum creatinine > 1.5. 
Hyperlipidcmia defined as requiring medication for elevated 
cholesterol r trigylcerides. 
Follow-up ranged from 3 to 108 months (mean 
46 months). Seventeen of the 22 patients who had 
successful dilation had failure during follow-up. All 
17 patients who had failure underwent artetiography 
because of clinical failure, and in each case this failure 
was associated with hemodynamic deterioration. No 
patient in this group had an asymptomatic reocclu- 
sion, but this finding may in part be due to the fact 
that only five patients remained without symptoms. 
Of the 17 patients with failure, 12 patients had 
recurrent IGPA stenosis, and five had popliteal artery 
occlusion. No patient had occlusion in a previously 
patent ibial artery. 
During follow-up two patients died of myocar- 
dial infarction, and no patient required an amputa- 
tion. With life-table analysis (Table II) clinical and 
hemodynamic success was 59%, 32%, and 20% at 1, 
2, and 3 years, respectively (Fig. 1). The average 
duration of benefit was 17 months (range 0 to 67 
months). 
Of the 14 patients treated for rest pain, two did 
not have successful dilation, and 10 had recurrent 
symptoms associated with hemodynamic deteriora- 
tion with a mean duration of benefit of 19 months. 
Of the 12 patients with failure, one subsequently had 
a repeat PTA, four had a repeat PTA followed by 
arterial bypass, six additional patients required arte- 
rial reconstruction, and one did not undergo any 
further treatment. 
Of the six patients treated for an ischemic wound, 
successful dilation could not be performed in one, 
and three had failure during follow-up. None of the 
four had satisfactory wound healing before failure 
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Fig. 1. Life-table plot of benefit of IGPATTA. 
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Table II. Life-table analysis for patients treated with IGPA PTA 
Interval Interval 
Interval No. at risk at No. of No. withdrawn failure patency 
(mo.) start of interval failures patent rate rate 
Cumulative 
patency 
(%) sE (~ 
0-1 25 3 0 0.12 0.88 100 0.0 
1-2 22 1 0 0.05 0.95 88 6.5 
2-3 21 1 0 0.05 0.95 84 7.3 
3-4 20 0 1 0.00 1.00 80 8.0 
4-5 19 2 0 0.11 0.89 80 8.2 
5-6 17 0 0 0.00 1.00 72 9.3 
6-7 17 1 0 0.06 0.94 72 9.3 
7-8 16 1 0 0.06 0.94 67 9.6 
8-9 15 0 0 0.00 1.00 63 9.9 
9-10 15 0 0 0.00 1.00 63 9.9 
10-11 15 1 0 0.07 0.93 63 9.9 
11-12 14 0 0 0.00 1.00 59 10.1 
12-15 14 1 1 0.07 0.93 59 10.1 
15-18 12 1 0 0.08 0.92 55 10.6 
18-21 11 3 0 0.27 0.73 50 10.7 
21-24 8 1 1 0.13 0.87 36 10.3 
24-30 6 1 0 0.17 0.83 32 10.7 
30-36 5 1 1 0.22 0.78 26 10.1 
(Table III). One patient died of myocardial infarction 
before arterial reconstruction could be performed, 
and the other three patients had subsequent bypass, 
with complete wound healing obtained in two. 
One of the five patients with claudication had 
persistent benefit during follow-up (Table III). The 
mean duration of benefit for all five patients was 27 
months. Before disease recurred, the average ABI 
improved from 0.65 to 0.89. Two patients under- 
went further intervention, with repeat PTA in one 
and repeat PTA followed by arterial bypass in the 
other. 
Overall, of the 20 (80%) patients either under- 
going unsuccessful dilation or having recurrent 
symptomatic stenosis or occlusion, eight (40%) were 
treated with repeat PTA. Six of the eight subse- 
quently required arterial reconstruction, and two 
underwent no further intervention. By life-table 
analysis, success for the eight patients who had repeat 
PTA was 44%, 29%, and 29% at 1, 2, and 3 years, 
respectively. The mean additional benefit was 8 
months (range 0 to 33 months). The interval from 
the initial PTA to the repeat dilatation ranged from 
4 to 49 months (average 29 months). 
Fourteen patients underwent subsequent arterial 
bypass after one or two failed dilations. Ten patients 
had femoral to tibioperoneal trunk bypass, two had 
femoral to tibial bypass, one had popliteal to tibial 
bypass, and one had popliteal patch angioplasty. The 
interval from the initial PTA to arterial reconstruc- 
tion ranged from 0 to 71 months. Eleven of the 14 
reconstructions remained patent during follow-up 
(mean duration 22 months, range 1 to 79 months), 
and all 11 patients with patent grafts had satisfactory 
wound healing or clinical improvement. 
Demographic variables, cardiovascular risk fac- 
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Table II I .  Results of IGPA PTA based on indication for procedure 
Failed during Mean benefit Follow-up 
Indication Patients (no.) Technical failure follow-up (Mo O operation 
Rest pain 14 2 10 19 10 
Ischemic ulcer 6 1 3 7 3 
Claudication 5 0 4 27 1 
tors, indication, and tibiai artery runoffwere analyzed 
to determine their effect on outcome. No variable 
was statistically significant in predicting failure after 
PTA. Patients with renal insufficiency, heart disease, 
and diabetes were at increased risk for recurrent 
symptomatic stenosis. Patients undergoing PTA for 
relief of  rest pain or an is chemic wound had recurrent 
stenosis ooner than patients treated for claudication, 
but the difference was not statistically significant 
(p = 0.85, p = 0.22). The number of patent tibial 
arteries did not affect outcome. 
DISCUSSION 
Although PTA is widely used for treatment of 
SFA and supragenicnlate popliteal artery occlusive 
disease, its use in patients with stenosis of the distal 
popliteal artery or tibioperoneai trunk has been more 
limited. This finding reflects everal factors including 
the lower incidence of localized IGPA stenosis com- 
pared with that of more proximal esions, increased 
technical requirements including finer guidewires 
and balloon catheters, potentially higher complica- 
tion rates, and limited data on the effectiveness of 
IGPA dilatation. 
Few studies have examined the effectiveness of 
PTA for distal popliteal lesions, and none has 
reported on isolated IPGA stenosis. Most studies on 
popliteal PTA have included primarily patients with 
tibial artery PTA. To make our study population 
more homogeneous, however, patients undergoing 
tibial artery angioplasty were excluded, because these 
patients tend to have more extensive and diffuse 
disease and would require a more distal bypass with 
lower expected patency and a higher incidence of 
complications. In addition, the resuks of tibial 
angioplasty are more dependent on technical skill 
with the use of finer catheters, balloons, and smaller 
arteries more prone to spasm or occlusion. 
Several studies on patients treated with either 
popliteal or tibia] angioplasty have reported better 
than 80% technical and clinical success. 3,7,s Durham 
et al. 9 reported a 2-year limb salvage rate of 77% in 
13 patients with diabetes undergoing tibial artery 
dilation, and Horvath et al. 1° obtained 75% cumu- 
lative patency at 2 years. Others have noted less 
favorable results. Brown et al., TM in spite of 
achieving better than 90% technical success, obtained 
clinical success in only 44% of patients at a mean 
follow-up of 25 months. 
In our experience technical success was achieved 
in 22 (92%) of 25 patients, with the three failures 
occurring early in the study and resulting from 
inability to cross the lesion with a wire. Our results 
confirm other reports that IGPA PTA is infrequently 
associated with mortality or major morbidity? We 
now use steerable guidewires (USCI-Bard, Billerica, 
Mass.) and glidewires for preocclusive lesions. In 
addition, the use of calcium channel blockers and 
nitroglycerin to prevent vasospasm, systemic heparin 
to minimize the risk of thrombosis or embolization, 
and digital imaging equipment to help select lesions 
and identify iatrogenic injuries have contributed to 
improved results both in our experience and the 
reports of  others. 7,9,13,14 With these advances we have 
been able to cross all subsequent stenoses uccess- 
fully, and we agree with others that technical success 
can be achieved in almost all patients with an isolated 
IGPA stenosis. 3"n'13'15'16 
In contrast o the experience of others, we found 
IGPA PTA did not provide effective sustained clinical 
benefit. Forty percent of patients had recurrent 
symptomatic stenosis within 1 year, and 80% had 
failure within 3 years. Sixteen (64%) patients re- 
quired a subsequent intervention, usually within the 
initial 12 months. 
Although patients with an ischemic lesion or rest 
pain were at higher risk for disease recurrence than 
patients with claudication, no statistically significant 
difference was found in the success rate for each 
group. For the 19 patients with rest pain or 
claudication, recurrent stenosis was invariably asso- 
ciated with symptomatic recurrence, and only seven 
of the 19 did not undergo further invasive treatment. 
For the six patients with ,an ischemic lesion, the 
average duration of benefit was only 7 months, and 
only two of the six had successful healing. 
These resuks are even more discouraging iven 
the nature of our patient population. Diabetes, 
cigarette use, and renal insufficiency have been 
associated with early disease recurrence but were 
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present in a minority of our patients. 8'17'18 Twenty 
percent of our patients did not have limb-threatening 
ischemia, and almost all had continuous in-line flow 
to the foot, variables found in other eports to predict 
the best long-term outcome.  11'17'19 
We found cardiovascular risk factors and the 
number of patent ibial arteries were unable to select 
patients likely to achieve sustained clinical benefit. 
Although renal insufficiency, heart disease, and 
diabetes were associated with earlier disease recur- 
rence, no variable was statistically significant in 
predicting success. However, the small number of 
patients in our study may have limited our ability to 
detect a small but present effect. 
We found disease recurrence after failed PTA was 
at the same site as the initial lesion. In part, this 
finding may reflect he rapid failure of IGPA PTA, 
allowing little time for progression of inflow or 
outflow lesions. The early recurrence suggests that 
myointimal hyperplasia or technical factors at the 
time of PTA are most likely responsible for the 
recurrent lesions rather than progression of athero- 
sclerotic disease. Although all patients underwent 
completion arteriography, arteriography may not be 
accurate in detecting residual flow disturbances atthe 
site of the PTA and may therefore not identify 
patients prone to early recurrence. 2°Duplex scanning 
may be more accurate in determining the effective- 
ness of PTA and identifying patients likely to have 
early recur rence .  2°'21 
Our study confirms other reports that PTA does 
not preclude or significantly alter subsequent opera- 
tion. 7,11 After review of the initial and follow-up 
arteriograms was performed, all 14 patients under- 
going bypass would have required the same opera- 
tion, if it had been performed at the time of the initial 
PTA. The localized disease in these patients fre- 
quently allows for patch angioplasty or a short bypass 
from the superficial femoral artery or proximal 
popliteal artery. Our results with operation for 
patients with recurrent stcnosis after PTA are similar 
to our results in patients who did not undergo initial 
dilation. 
Several adjunctive measures have been used to 
improve the success ofinfrageniculate PTA, but none 
has been shown to improve long-term outcome. 22,23 
We found aspirin and persantine were not associated 
with longer clinical benefit. Bull et al.8 treated all 
patients with warfarin (Coumadin) and reported 
83% 3-year clinical success for patients with a single 
stenosis, but the benefit of Coumadin has not been 
confirmed in controlle~t or prospective trials. Other 
reports have not found Coumadin to improve 
patency. 4 Jorgenson has advocated limiting the area 
of PTA and using the smallest necessary balloon 
catheter, but the clinical benefit of this approach as 
not been shown. 24 Thrombolytic therapy may be 
helpful for occlusive lesions but has not been 
advocated for patent but stenotic arteries. 
Repeat PTA has been advocated for treatment of 
recurrent symptomatic stenosis. Although some re- 
ports have found long-term clinical benefit, others 
have found repeat PTA is frequently unsuccessful or
not indicated, n Bull et al. 8 noted repeat PTA was 
possible in only four of 23 patients. We found it to 
be less effective than the initial procedure, with 
clinical benefit of 29% at 3 years and a mean benefit 
of only 8 months. We do not recommend its use in 
these patients. 
After PTA, patients should have regular fol- 
low-up clinical examinations including measurement 
of the ABI at at least 3-month intervals for the first 
year and routinely thereafter. In our experience and in 
the reports of others ,  2s most  recurrent lesions de- 
velop early and can be detected with noninvasive 
evaluation. 25,26 Duplex scanning can then be used to 
identify and localize the recurrent lesion, with arteri- 
ography reserved for patients requiring further inter- 
vention. Regular surveillance may identify stenotic 
lesions before subsequent occlusion occurs. 8
Several reports now advocate IGPA PTA for 
patients with limb-threatening ischemia nd some for 
the treatment of claudication.3,4 These recommenda- 
tions are based on studies reporting benefit of PTA 
similar to arterial bypass with native vein and superior 
to bypass with prosthetic grafts. Other suggested 
advantages of initial IGPA PTA include (1) preser- 
vation of the saphenous vein for future use, (2) 
avoiding the inherent morbidity associated with 
operation, (3) providing a temporary increase in 
distal perfusion to heal an ischemic lesion, obviating 
the need for arterial reconstruction should restenosis 
develop, and (4) an initial cost saving compared with 
revascularization.3,~1,15 
Our experience does not support these advan- 
tages. IGPA PTA results in frequent early failure, 
with most patients requiring further intervention. 
Patients with claudication and rest pain invariably 
had symptomatic recurrence associated with PTA 
failure. For patients with an ischemic lesion, the 
temporary increase in distal perfusion was usually not 
sufficient for complete healing. Attempting to pre- 
serve the saphenous vein is unjustified, because in 
most cases the vein will be required for bypass during 
the early follow-up period, and studies have found 
the likelihood the vein will be required for bypass in 
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other locations is small. Attempted PTA also risks 
arterial dissection, occlusion, or groin hematoma, 
and the systemic complications ofadditional contrast 
administration. 
At our institution patients are charged from 
$16,000 to $21,000 for an uncomplicated PTA 
depending on whether the procedure is undertaken i  
the operating room or angiography suite and 
whether separate initial diagnostic arteriography is 
performed. This cost is higher for patients requiring 
continued observation ortreatment ofcomplications. 
For all admissions Hunink 27 found the mean hospital 
cost for angioplasty was $16,341 and for bypass was 
$17,276. 
PTA of stenotic lesions of the popliteal artery and 
tibioperoneal trunk are not long-lasting in the vast 
majority of patients. Procedures done for limb 
salvage are very likely going to require operative 
intervention. PTA should be reserved for patients 
with limb-threatening ischemia nd major contrain- 
dications to operation. 
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DISCUSSION 
Dr. Peter A. Schneider (Salt Lake City, Utah). One 
thing is clear from clinical experience and reinforced by this 
study: more and more different kinds of lesions will be 
dilatable. The problem is in understanding whether we arc 
helping the patient. I will confine my comments and 
questions to the three factors that I believc will determine 
the eventual clinical utility of endovascular techniques: 
patient selection, technique, and cost. 
The selection of patients based on the clinical setting, 
of which the angiographic picture is only a small part, 
continues to be the cornerstonc of success. Dr. Treiman's 
article reminds us of this fact, showing excellent early 
technical results and a desperate need for close clinical 
follow-up. 
How many different surgeons and radiologists were 
involved in patient selection, and do you think that 
variability in practice patterns influenced results? 
Should the procedure be considered at all among 
patients with claudication? The claudicators in the study 
did best as usual, proving again the endovascular dictum: 
best results in those who need it least. If the claudicators are 
factored out, the overall benefit of the procedure is down 
to 15 months. 
The technical aspects of all endovascular procedures 
form a moving target because of continual advances in 
technology and experience. Three technical developments 
were mentioned in the article as responsible for improved 
results. Teflon-coated guidewires have made crossing 
lesions easier and faster. Lower profile balloons have made 
tibial PTA more feasible but are usually not required for 
popliteal esions. Digital subtraction arteriography is fre- 
quently mentioned as a technical advance, but I remain 
unconvinced whether it affects results. In general, digital 
subtraction arteriography increases convenience but de- 
creases resolution (versus cut film). 
I prefer to approach these lesions using an ipsilateral 
antegrade f moral puncture and an introducing sheath. The 
location of entry into the arterial system permits maximal 
control of guidewires and catheters, and the sheath allows 
interim contrast injection while leaving the guidewire in 
place across the lesion. Two notes of caution in PTA of the 
infrageniculate popliteal: (1) perigeniculate collaterals fre- 
quently parallel the popliteal and can be easily entered with 
a hydrophilic guidewire, so the position of the guidewire 
must be confirmed before passing a balloon, and (2) 
opportunities for subintimal guidewire passage are in- 
creased because there are often areas of very soft artery, 
especially the retrogeniculate popliteal, interspersed with 
bulky eccentric alcified plaque. 
Can you further characterize the study lesions? Short 
versus long? Tibioperoneal trunk versus below-knee 
popliteal? Did differences affect results? 
The third area of interest is cost. We cannot expect his 
study to answer the question that most of our hospital 
administrators are unable to answer: what does anything 
actually cost? But we also should not view this study as an 
in-depth analysis of cost. You reported the charges for the 
procedures as being between $16,000 and $21,000 each; 
this may be more a reflection of overhead than the resources 
required to perform the procedure. The relative charges for 
alternative surgical procedures were not included for 
comparison. Charges grossly overstate costs, often by 50%. 
The digital subtraction arteriography for distal bypass is 
generally considered a money loser and that for PTA a 
money maker: even the government pays more for balloon 
angioplasty than it is worth. 
In the case of PTA, the classic surgery/radiology 
paradigm is very cost-inefficient. The cost of PTA in the 
study could have been cut by a quarter to a third if it had 
been performed at the time of the primary angiogram 
rather than as a second procedure. 
Dr. Gerald S. Treirnan. There were eight vascular 
surgeons involved in the care of patients, and there were 
four different radiologists. Practice patterns influenced the 
selection of patients who were referred for possible PTA. 
However, all patients undergoing PTA had similar char- 
acteristics. We excluded from this study patients who did 
not meet the established criteria. 
All patients in this study had a focal infrageniculate 
popliteal or tibioperoneal trunk stenosis, which was dilated 
by the same group of radiologists. All patients had similar 
follow-up. Patients with a similar lesion but who under- 
went operation were not included with this study. 
Patients needing treatment for disabling claudication 
should undergo operation. The decision to proceed with 
any intervention obviously depends on the clinical judg- 
ment of the physician and the wishes of the patient. 
Almost all lesions were 1 to 3 cm in length. Most 
lesions involved the distal popliteal artery, although we did 
not specifically analyze our results based on lesion length 
between 1 and 5 cm, or whether the lesion involved the 
popliteal or the tibioperoneal trunk. 
We agree cut films are generally superior to digital 
subtraction arteriography. We also generally use an ipsi- 
lateral approach with a sheath for the same reasons, as we 
feel it gives us better ability to manipulate the catheter. 
Subintimal dissection of the guidewire can certainly 
occur and resulted in one popliteal artery dissection in our 
study. Its occurrence is in part related to the ability of the 
person doing the procedure. 
As for cost versus charges, there is frequently little 
relationship between the two. The bottom line is that 
whatever the cost and whatever the charges of doing the 
PTA, it is an added cost over the cost of just doing an 
operation and one that is probably not worth it because the 
additional benefit is small. 
Costs of PTA could be reduced ifPTA was done at the 
time of diagnostic arteriography. In our experience, most 
of the time the procedure was being done by the 
interventional radiologist, and the vascular surgeon was not 
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always available for immediate consultation. If the vascular 
surgeon did the procedure or was involved and present at 
the initial time, PTA could be done at the same setting with 
a cost savings. 
Dr. George Andros (Burbank, Calif.). I very much 
enjoyed this article and urge everyone to read the last part 
of it because the conclusions are the correct ones, namely, 
that the procedure should be reserved for patients who have 
a short life expectancy or cannot olerate surgery. This is 
our current practice. 
In the past we described intraoperative outflow balloon 
angioplasty below a femoral-popliteal bypass graft. When 
we described our procedure we admonished against its use 
except in highly selected cases, and I think that your data 
support hat advice. 
How do distal popliteal esions compare with infra- 
popliteal esions? Likewise, it would be worth knowing 
how your suprageniculate popliteals arteries fair versus 
your infrageniculates lesions. I believe that would an 
important bit of comparative information. 
You suggest that the finding of the subintimal dissec- 
tion may be a predictor of poor outcome, but as you know 
we all look for a nice crescent of dissection as an indicator 
of adequate fracture of the plaque. Could you tell us how 
that particular patient whom you described turned out 
acutely and in the long term? There is also some interesting 
work by Peter Bell in Leicester, who reported a large series 
in which subintimal balloon angioplasty was intentionally 
performed, and the results were surprisingly good. 
Finally, you raise the question of costs, and I offer to 
you that we do not only know the charges, let alone the 
costs, but I would doubt that we could even get accurate 
data on collections. 
Dr. Treiman. We looked at popliteal and tibioperoneal 
trunk as opposed to tibial angioplasties, because (1) tibial 
PTA is much more technician-dependent, a d(2) there is 
much more variability in results. It is assumed, probably 
incorrectly, by many interventional radiologists and many 
other people, that IGPA PTA is not as technically 
demanding, and therefore more uniform results can be 
expected from different institutions. Now whether that is 
true, one can argue, but that was part of the thinking. 
We separated the below-knee popliteal from the 
above-knee popliteal, since the operative procedure re- 
quired would be different. With an above-knee popliteal or 
distal superficial femoral artery lesion, patients could 
potentially be treated with an above-knee bypass. Patients 
with a tibioperoneal trunk lesion would require a distal 
tibioperoneal trunk or a tibial bypass, which certainly is a 
bigger procedure with lower expected patency and a longer 
operation time. 
In addition, we thought it was becoming rather 
standard to dilate above-knee popliteal arteries and SFAs, 
and there certainly was a fair amount of literature on that 
subject. However, no studies had specifically looked at the 
below-knee popliteal or the tibioperoneal trunk lesions. 
In answer to the question of what happened to the 
patient with the dissection, that patient did well. It was 
detected under fluoroscopy and DSA, which showed afalse 
channel in the popliteal artery, which then reconstituted 
distally. Ultimately, the dissection resolved, and follow-up 
arteriography 1 week later showed apatent popliteal artery. 
